Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an update.
C-Rad AB reported a 6% increase in order intake for the second quarter of 2025, driven by major contracts in EMEA and the USA, despite a challenging macroeconomic environment. However, revenues decreased by 19% due to a strong comparison quarter in China, impacting overall profitability. The company is focusing on expanding its service business, operational efficiency, and product innovation to achieve its medium-term financial targets of organic growth and improved operating margins.
More about C-Rad AB Class B
C-Rad AB is a company operating in the medical technology industry, specializing in Surface Guided Radiation Therapy (SGRT) solutions. Their primary products and services focus on enhancing precision and safety in radiation therapy, with a market focus on healthcare providers globally.
Average Trading Volume: 32,030
Current Market Cap: SEK1.16B
For detailed information about CRAD.B stock, go to TipRanks’ Stock Analysis page.